IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Ridker, PM; Devalaraja, M; Baeres, FMM; Engelmann, MDM; Hovingh, GK; Ivkovic, M; Lo, L; Kling, D; Pergola, P; Raj, D; Libby, P; Davidson, M

Ridker, PM (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA.

LANCET, 2021; 397 (10289): 2060

Abstract

Background IL-6 has emerged as a pivotal factor in atherothrombosis. Yet, the safety and efficacy of IL-6 inhibition among individuals at high atheros......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索